Werewolf Therapeutics, Inc.
NASDAQ:HOWLBiotechnology
+$0.06 today
- Market cap
- $50.06M
- Beta
- 0.29
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.71
Volume 1.85M
Average 5.09M
HOWL Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Werewolf Therapeutics, Inc.NASDAQ: HOWL
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation declines year over year
Q2 FY2026 stock-based compensation of $419K fell 76.6% year over year, behind the -50.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 54.9% from the prior quarter. Over 3 fiscal years it compounded at -5.5% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -76.6% toward the trailing-twelve-month pace of -50.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.25M USD
- Year-over-year change
- -29.2%
- 4-year CAGR
- +11.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.25M | -29.2% |
| FY2024 | 2024-12-31 | 8.83M | +10.2% |
| FY2023 | 2023-12-31 | 8.01M | +8.2% |
| FY2022 | 2022-12-31 | 7.4M | +80.7% |
| FY2021 | 2021-12-31 | 4.1M | — |
Stock-Based Compensation vs competitors
How HOWL compares with its peers on the latest reported figures
- HOWL's LTM Jun 2026 stock-based compensation of $3.79M is the 4th largest of the 8 companies compared; the peer median is $3.45M.
- Its year-over-year change of -50.8% is the 7th highest of 8, against a peer median of -37.2%.
- Stock-based compensation amounts to 18.1% of revenue for HOWL, versus a peer median of 16.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $4.27B | +453006.6% | — | — |
| LTM Mar 2026 | $12.39M | -37.2% | -5.9% | — | |
| LTM Mar 2026 | $5.14M | -37.3% | +4.9% | 1543.3% | |
| LTM Jun 2026 | $3.79M | -50.8% | -5.5% | 18.1% | |
| LTM Mar 2026 | $3.45M | -44.6% | -20.7% | 10.6% | |
| LTM Mar 2026 | $2.72M | -37.2% | -10.8% | — | |
| LTM Mar 2026 | $579K | -107.3% | +11.5% | — | |
| LTM Mar 2026 | $367K | +43.4% | -60.2% | 16.0% | |
| Peer median (excluding HOWL) | $3.45M | -37.2% | -8.4% | 16.0% | |
Competitors are the stored peer set for HOWL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (49.98M) | (53.81M) | (37.37M) | (70.52M) | (60.82M) |
| Depreciation & Amortization | 216K | 1.1M | 1.76M | 1.81M | 1.63M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.1M | 7.4M | 8.01M | 8.83M | 6.25M |
| Change in Working Capital | 2.28M | 2.54M | (5.89M) | 2.53M | (8.21M) |
| Accounts Receivables | 0 | (6.93M) | 5.58M | 1.35M | 0 |
| Inventory | 0 | 6.93M | 0 | 0 | 0 |
| Accounts Payables | 1.01M | (883K) | (4.34M) | 3.46M | (7.5M) |
| Other Working Capital | 1.27M | 3.42M | (7.14M) | (2.28M) | (707K) |
| Other Non-Cash Items | 519K | 2.17M | 878K | 1.16M | 856K |
| Operating Cash Flow | (42.88M) | (40.6M) | (32.61M) | (56.19M) | (60.29M) |
| Capital Expenditures | (498K) | (3.61M) | (769K) | (254K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (498K) | (3.61M) | (769K) | (254K) | 0 |
| Debt Repayment | 0 | 0 | 40M | (10M) | 0 |
| Common Stock Issued | 111.6M | 15.74M | 18.33M | 23.58M | 6.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.17M) | 166K | 100K | (496K) | 0 |
| Financing Cash Flow | 109.43M | 15.91M | 58.43M | 13.08M | 6.03M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 66.05M | (28.3M) | 25.05M | (43.36M) | (54.26M) |
| Free Cash Flow | (43.37M) | (44.21M) | (33.38M) | (56.44M) | (60.29M) |
Werewolf Therapeutics, Inc.
NASDAQ:HOWL
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.